References of "Pirotte, Bernard"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailDesign and pharmacological evaluation of recently developed 6-substituted 3-bromophenyl 2-oxo-2H-1-benzopyran 3-carboxylate derivatives as putative inhibitors of cell invasion
Kempen, I.; Frankenne, F.; Telliez, A. et al

in Fundamental & Clinical Pharmacology (2004)

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailSynthésis and pharmacological evaluation of original thromboxane A2 receptor antagonists derived from BM-573
Hanson, Julien ULg; Renard, Jean-François ULg; Neven, P. et al

in Fundamental & Clinical Pharmacology (2004)

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detailNew trends in the design of drugs against Alzheimer's disease
Francotte, Pierre ULg; Graindorge, Emmanuel; Boverie, Stéphane et al

in Current Medicinal Chemistry (2004), 11(13), 1757-1778

First described by Alois Alzheimer in 1907, Alzheimer's disease (AD) is the most common dementia type, affecting approximately 20 million people worldwide. As the population is getting older, AD is a ... [more ▼]

First described by Alois Alzheimer in 1907, Alzheimer's disease (AD) is the most common dementia type, affecting approximately 20 million people worldwide. As the population is getting older, AD is a growing health problem. AD is currently treated by symptomatic drugs, the acetylcholinesterase inhibitors. based on the cholinergic hypothesis (1976). During the past decade, advances in neurobiology have conducted to the identification of new targets. Although some of these innovative approaches tend to delay onset of AD, others are still symptomatic. In this review, we present an overview of the several strategies and new classes of compounds against AD. [less ▲]

Detailed reference viewed: 33 (11 ULg)
Peer Reviewed
See detailBM-613, a new thromboxane A2 antagonist, is characterized by a preferential activity on platelet thromboxane A2 receptors
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

Poster (2003, December)

Detailed reference viewed: 6 (0 ULg)
Peer Reviewed
See detailPharmacological evaluation of BM-573, a dual thromboxane A2 receptor antagonist and thromboxane synthase inhibitor, as potential anti-metastatic agent
De Leval, X.; Dassesse, T.; Benoît, V. et al

Poster (2003, December)

Detailed reference viewed: 4 (0 ULg)
Peer Reviewed
See detailBM-613, a new thromboxane A2 antagonist, is characterized by a preferential activity on platelet thromboxane A2 receptors
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

Poster (2003, November 22)

Detailed reference viewed: 3 (1 ULg)
Peer Reviewed
See detailEffects of cromakalim analogues on rat pancreatic B-cells, rat aorta rings and rat uterus. Study of their mechanism of action as potassium channel activators
Sebille, S.; Boverie, S.; Becker, B. et al

Poster (2003, November 22)

Detailed reference viewed: 12 (0 ULg)
Full Text
See detailPharmacological evaluation of BM-573, a dual thromboxane A(2) receptor antagonist and thromboxane synthase inhibitor, as potential anti-metastatic agent
de Leval, X. J.; Dassesse, T.; Benoit, V. et al

in Blood (2003, November 16), 102(11, Part 2), 72

Detailed reference viewed: 11 (4 ULg)
Peer Reviewed
See detailTowards tissue-selective KATP channel openers
Lebrun, P.; Antoine, M. H.; Dabrowski, M. et al

Poster (2003, July)

Detailed reference viewed: 4 (0 ULg)
Peer Reviewed
See detailSynthèse et évaluation pharmacologique de N-pyridinyl-alkanesulfonamides apparentés au nimésulide
Julemont, F.; De Leval, X.; Michaux, C. et al

Poster (2003, May)

Detailed reference viewed: 3 (0 ULg)
Peer Reviewed
See detailSynthèse et évaluation biologique de nouvelles coumarines en tant qu’anticoagulants potentiels
Pochet, L.; Rolin, S.; Morel, M. et al

Poster (2003, May)

Detailed reference viewed: 17 (0 ULg)
Peer Reviewed
See detailPyridinic sulfonamides as potential COX-2 inhibitors
Julemont, F.; De Leval, X.; Damas, J. et al

Poster (2003, May)

Detailed reference viewed: 7 (0 ULg)
Peer Reviewed
See detailPharmacological evaluation of the thromboxane A2 receptor antagonist BM-613
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

Poster (2003, May)

Detailed reference viewed: 2 (0 ULg)